Placebo response in antipsychotic clinical trials: a meta-analysis.
about
The role of inflammation in schizophreniaManipulating the Placebo Response in Experimental Pain by Altering Doctor's Performance StyleWhat can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Placebo Response in Repetitive Transcranial Magnetic Stimulation Trials of Treatment of Auditory Hallucinations in Schizophrenia: A Meta-Analysis.Certainty of genuine treatment increases drug responses among intellectually disabled patients.Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Placebo eff ects in psychiatry: mediators and moderators.Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical TrialsA double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALSPredictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysisThe comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Mechanisms of the placebo effect in pain and psychiatric disorders.Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Increasing placebo response in antipsychotic trials: a clinical perspective.Clinical Trials to Gain FDA Approval for Computerized Cognitive Training: What Is the Ideal Control Condition?Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder.Blinded sample size re-estimation in three-arm trials with 'gold standard' design.Methods for assessing and controlling placebo effects.A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials.[Non-invasive brain stimulation for treatment of schizophrenic psychoses].Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder.Recruitment and retention strategies in mental health trials - A systematic review
P2860
Q26779719-2A39374D-D10D-41C8-AF61-F96C54738852Q27304510-D301AC1A-AAEE-401C-8EAD-A44CEF48B02CQ28083481-E9217D99-9575-471D-92BB-CE393E5995EBQ30711964-58005705-462F-4CD5-B33B-E78AA623FAE3Q33726997-5CB28E81-2CE7-4E21-8741-60DA8C86175EQ34487591-AE063B28-EE64-48CE-A825-C997ED44EC5CQ35207492-2EE760C9-A1A9-45A1-83B4-B833632E9372Q36038231-436521B2-C622-4A4E-9256-504FDB24D1D8Q36475355-920EC51F-B3D0-421F-B846-01585F99B9EFQ36859704-87D594C3-6205-4400-92AF-FD5343168A50Q37041164-DBFDD7B0-1E55-4717-BAB6-F259B4FF8A40Q37347743-D6078175-BFDF-4BA0-B9F2-E96E8225F6B1Q38672790-0A6912D4-EDAB-4033-89F8-6BDD3CEC06A3Q38676860-5AD0477C-AC59-49C6-BAE8-9FA3C69A082AQ38750121-B7780654-F2BF-4FA2-A96E-15EE2B5CFBEEQ38784077-23223291-9DCA-41C6-8C96-10812EA266D2Q38787906-D2A82D58-F1A9-4D46-8938-5665AB773D55Q39233330-0D1D3D6B-0737-460C-931D-16223709C795Q40783366-A1F0AB8C-E869-41FB-A3A2-29BCE1D3D465Q41643206-C8589D89-E158-4672-89B6-9828FF6D5C38Q47149850-B4088E3F-9705-47A4-9A39-B35380681CC0Q47206643-45E678C7-7BA2-4B5A-AC71-59F562451863Q47248824-6BC665B4-6A1E-4FDC-B018-94832F8F9845Q47579231-CE103A58-4DA7-492C-9D2C-751980835DDEQ49342341-118B41A2-8F12-4E42-8F02-226B0ADAE48AQ53360993-3998E146-E651-4770-8795-4ADE4AAE53B0Q55313130-03E1EAF0-65BA-4521-928D-E321092E4CDCQ58695939-CCE21FB2-0659-4EFB-A8E6-098AF77D4A3A
P2860
Placebo response in antipsychotic clinical trials: a meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Placebo response in antipsychotic clinical trials: a meta-analysis.
@ast
Placebo response in antipsychotic clinical trials: a meta-analysis.
@en
Placebo response in antipsychotic clinical trials: a meta-analysis.
@nl
type
label
Placebo response in antipsychotic clinical trials: a meta-analysis.
@ast
Placebo response in antipsychotic clinical trials: a meta-analysis.
@en
Placebo response in antipsychotic clinical trials: a meta-analysis.
@nl
prefLabel
Placebo response in antipsychotic clinical trials: a meta-analysis.
@ast
Placebo response in antipsychotic clinical trials: a meta-analysis.
@en
Placebo response in antipsychotic clinical trials: a meta-analysis.
@nl
P2093
P2860
P1433
P1476
Placebo response in antipsychotic clinical trials: a meta-analysis.
@en
P2093
Bret R Rutherford
Emily Pott
Jane M Tandler
Jeffrey A Lieberman
Melanie M Wall
Steven P Roose
P2860
P304
P356
10.1001/JAMAPSYCHIATRY.2014.1319
P407
P577
2014-12-01T00:00:00Z